Oxytocin's potential to boost MRI-HIFU efficacy in patients to be evaluated in planned trial

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MRI-HIFU) is a cutting-edge, non-invasive therapeutic modality used to precisely ablate target tissues, commonly for conditions like uterine fibroids, essential tremor, and certain cancers. Despite its advantages, challenges persist in achieving complete and consistent ablation, managing patient discomfort during lengthy procedures, and optimizing tissue response. Oxytocin, a potent neuropeptide and neurohormone, is well-known for its roles in smooth muscle contraction (e.g., uterine contractions) and neuromodulation, including effects on pain perception and blood flow. Researchers hypothesize that oxytocin's physiological actions could synergistically enhance HIFU efficacy by potentially improving tissue targeting, reducing local blood supply to the treatment area, or mitigating procedural pain, thereby addressing current limitations and improving patient outcomes.

This pilot project outlines a randomized controlled trial designed to investigate the adjunctive role of oxytocin in MRI-HIFU. Patients scheduled for MRI-HIFU treatment will be randomly assigned to receive oxytocin (specific dose, route, and timing unspecified in this abstract) or a control (likely placebo or standard care) during their procedure. The study's primary objective is to evaluate the impact of oxytocin on treatment efficacy, which will be assessed through comprehensive patient-reported symptom questionnaires and detailed analysis of imaging data collected post-treatment.